A detailed history of Wellington Management Group LLP transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 262,040 shares of TSVT stock, worth $854,250. This represents 0.0% of its overall portfolio holdings.

Number of Shares
262,040
Previous 240,367 9.02%
Holding current value
$854,250
Previous $925,000 33.62%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.85 - $5.05 $83,441 - $109,448
21,673 Added 9.02%
262,040 $1.24 Million
Q2 2024

Aug 13, 2024

BUY
$3.6 - $5.79 $137,858 - $221,722
38,294 Added 18.95%
240,367 $925,000
Q1 2024

May 15, 2024

BUY
$3.09 - $6.0 $624,405 - $1.21 Million
202,073 New
202,073 $1.08 Million
Q4 2023

Feb 12, 2024

BUY
$1.57 - $4.58 $810,049 - $2.36 Million
515,955 New
515,955 $2.2 Million
Q3 2023

Nov 14, 2023

BUY
$3.14 - $11.2 $359,683 - $1.28 Million
114,549 Added 3.98%
2,994,471 $11.7 Million
Q2 2023

Aug 14, 2023

BUY
$8.45 - $12.48 $933,555 - $1.38 Million
110,480 Added 3.99%
2,879,922 $29.1 Million
Q1 2023

May 12, 2023

SELL
$9.21 - $14.98 $2.56 Million - $4.17 Million
-278,144 Reduced 9.13%
2,769,442 $28.2 Million
Q4 2022

Feb 13, 2023

SELL
$8.57 - $17.0 $1.41 Million - $2.8 Million
-164,425 Reduced 5.12%
3,047,586 $28.6 Million
Q3 2022

Nov 14, 2022

BUY
$12.56 - $17.54 $3.85 Million - $5.38 Million
306,644 Added 10.55%
3,212,011 $46.7 Million
Q2 2022

Aug 15, 2022

BUY
$10.55 - $18.81 $4.15 Million - $7.4 Million
393,412 Added 15.66%
2,905,367 $38.4 Million
Q1 2022

May 16, 2022

BUY
$11.67 - $26.72 $4.92 Million - $11.3 Million
421,700 Added 20.17%
2,511,955 $42.9 Million
Q4 2021

Feb 11, 2022

BUY
$13.77 - $42.56 $28.8 Million - $89 Million
2,090,255 New
2,090,255 $53.6 Million

Others Institutions Holding TSVT

About 2seventy bio, Inc.


  • Ticker TSVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,873,600
  • Market Cap $123M
  • Description
  • 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...
More about TSVT
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.